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Introduction {#sec1}
============

Asthma, one of the most common chronic diseases, especially among children, is a complex inflammatory disorder characterized by chronic and persistent inflammation of the airways ([@bib21]). Currently, asthma affects more than 300 million people worldwide, especially in developing countries ([@bib31], [@bib43]). Despite advances in pharmacological therapy, the prevalence of asthma is increasing steeply. Over the past decades, the mechanisms underlying the pathogenesis of asthma have been intensively studied, and epithelial cell injury is considered to be a major cause of asthma ([@bib20]). It has been reported that mitochondrial dysfunction causes airway epithelial cell injury and apoptosis, leading to allergic airway inflammation ([@bib5], [@bib30], [@bib36]). Given the accumulating evidence linking mitochondrial injury and inflammation, targeting mitochondrial dysfunction of epithelial cells may be a strategy for asthma therapy.

An increasing number of studies have demonstrated that mesenchymal stem cell (MSC)-based therapy shows promising results for allergic airway inflammation ([@bib8], [@bib9], [@bib39]). We have demonstrated that MSCs derived from induced pluripotent stem cells (iPSC-MSCs) not only effectively inhibit allergic airway inflammation and alleviate asthma in a mouse model but also modulate T cell phenotypes in allergic rhinitis patients ([@bib11], [@bib37]), indicating that iPSC-MSC-based therapy could be relevant to the treatment of allergic airway inflammation. MSCs derived from adult tissues, such as bone marrow (BM), have limited proliferative capacities and exhibit great variability in cell quality across different donors, which limits their therapeutic benefits, especially in clinical applications ([@bib7]). We previously found that iPSC-MSCs had lower immunogenicity and superior survival and engraftment following transplantation in a mouse ischemia model compared with BM-MSCs ([@bib38]). We also reported that iPSC-MSCs have a better cell proliferation ability, longer life span (more than 50 passages), and less cell senescence than BM-MSCs ([@bib12], [@bib24]). Recent studies have demonstrated that BM-MSCs exert beneficial effects via mitochondrial transfer in mouse models of acute lung injury and allergic airway inflammation ([@bib1], [@bib16]). We previously reported that mitochondrial transfer from iPSC-MSCs to airway epithelial cells and airway smooth muscle cells mainly occurs via tunneling nanotubes (TNTs) to rescue lung injury induced by cigarette smoke or oxidative stress agents ([@bib22], [@bib23]). Nevertheless, whether the alleviation of asthma inflammation by iPSC-MSCs is attributed to mitochondria donation and the possible mechanisms of this effect remain unclear.

Connexin 43 (CX43), a gap junction protein that regulates a cell connection channel or TNTs, mediates organelle exchange or migration between cells. BM-MSCs were demonstrated to protect against acute lung injury via CX43-mediated mitochondrial donation to alveoli, suggesting that CX43 plays a prominent role in regulating mitochondrial transfer ([@bib16]). Additionally, we reported that CX43 is upregulated in mouse lungs during asthma ([@bib42]), which is essential for mitochondrial transfer. Therefore, we hypothesized that CX43-regulated TNT formation is important for mitochondrial transfer from iPSC-MSCs to the injured bronchial epithelial cells, thereby inhibiting asthma inflammation.

In this study, we found that local transplantation of iPSC-MSCs alleviated airway inflammation and rescued mitochondrial dysfunction in a mouse model of asthma. We observed that CX43 regulated TNT formation between iPSC-MSCs and epithelial cells *in vitro* and further observed that iPSC-MSCs donated the mitochondria to the dysfunctional mitochondrial epithelial cells in mice and *in vitro*. Notably, we showed that CX43 contributes to mitochondrial transfer via regulating TNT formation in iPSC-MSCs.

Results {#sec2}
=======

Local Transplantation of iPSC-MSCs Alleviates Ovalbumin-Induced Asthma Inflammation in Mice {#sec2.1}
-------------------------------------------------------------------------------------------

We previously reported that intravenous injection of iPSC-MSCs prevented allergic airway inflammation in mice ([@bib37]). To investigate the effects of iPSC-MSCs on epithelial cells, two clones of iPSC-MSCs were intratracheally administered in a mouse model of asthma. Compared with that in the control group, the administration of ovalbumin (OVA) significantly increased lung inflammatory infiltration, indicating the successful establishment of an asthma animal model ([Figure 1](#fig1){ref-type="fig"}A). H&E and periodic acid--Schiff (PAS) staining showed that, compared with the OVA group, local transplantation of N1-iPSC-MSCs and iMR90-iPSC-MSCs significantly alleviated peribronchial and perivessel inflammation and decreased mucus secretion in hyperplastic goblet cells ([Figure 1](#fig1){ref-type="fig"}A). The inflammation score and mucus hypersecretion were significantly decreased by more than 50% in the N1-iPSC-MSC and iMR90-iPSC-MSC groups compared with those in the OVA group ([Figure 1](#fig1){ref-type="fig"}B, p \< 0.01). Administration of iPSC-MSCs significantly alleviated the airway hyperresponsiveness at different methacholine concentrations (6.25, 12.5, 25, 50, and 100 mg/mL) ([Figure S1](#mmc1){ref-type="supplementary-material"}). Furthermore, eosinophils, macrophages, lymphocytes, neutrophils, and total inflammatory cells in the bronchoalveolar lavage fluid (BALF) were greatly reduced in the N1-iPSC-MSC and iMR90-iPSC-MSC groups compared with those in the OVA group ([Figure 1](#fig1){ref-type="fig"}C). Similarly, the T helper 2 (Th2) cytokine (interleukin \[IL\]-4, IL-5, and IL-13) levels in BALF, immunoglobulin (Ig) E levels in serum, and epithelium-derived cytokine (IL-33 and thymic stromal lymphopoietin \[TSLP\]) levels in lung homogenates were much lower in the iPSC-MSC-treated group than in the OVA group ([Figures 1](#fig1){ref-type="fig"}D--1F, p \< 0.001). Therefore, local transplantation of iPSC-MSCs significantly alleviates asthma inflammation induced by OVA in mice.Figure 1Transplantation of iPSC-MSCs Significantly Alleviates Asthma Inflammation via Local Application in Mice(A) Representative photomicrographs of H&E- and PAS-stained lung sections from each group showing inflammatory infiltrates (lung H&E, shown by arrows) and mucus accumulation at the luminal surface of the bronchi (lung PAS staining, shown by arrows) in lungs from different groups.(B) Statistical analysis of the inflammation score and mucus hypersecretion as quantified by H&E/PAS staining (n = 6).(C--F) The inflammatory cell counts in BALF (C, n = 6); cytokine IL-4, IL-5, and IL-13 levels in BALF (D, n = 6); IgE, IgG1, and IgG2a levels in serum (E, n = 6); and TSLP and IL-33 levels in lung homogenates (F, n = 6) were measured using ELISA.Data are presented as the mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}. BALF, bronchoalveolar lavage fluid; HE (Br), H&E-stained bronchia; HE (Ve), H&E-stained vessels.

iPSC-MSCs Effectively Reduce OVA-Induced Mitochondrial Dysfunction in the Lung {#sec2.2}
------------------------------------------------------------------------------

We next investigated the survival and distribution of iPSC-MSCs post transplantation. The engraftment of GFP-transfected iPSC-MSCs (GFP-iPSC-MSCs) was detected by fluorescence microscopy and flow cytometry at different time points (1 hr, 4 hr, 8 hr, 24 hr, and 96 hr). We observed the survival and distribution of GFP-iPSC-MSCs in the lung at 1 and 4 hr after transplantation in both the OVA group and the PBS group. The number of GFP-iPSC-MSCs gradually decreased in a time-dependent manner and disappeared after 1 day in the PBS group. However, some GFP-iPSC-MSCs were still detected in the lungs even at 4 days after transplantation in the OVA-treated mice ([Figure 2](#fig2){ref-type="fig"}A). These results were further verified by flow cytometry. One hour after transplantation, more than 6% of GFP^+^ cells in the cell population were detected in both the OVA group and the PBS group. Although the percentage of GFP^+^ cells declined over time, engrafted cells were still detected up to 4 days later in the OVA-treated mice, suggesting that the engraftment of iPSC-MSCs into the lungs of OVA-treated mice was much higher than that in the lungs of controls ([Figure 2](#fig2){ref-type="fig"}B).Figure 2iPSC-MSC Treatment Reduces the Ultrastructural Changes and Mitochondrial Dysfunction in Injured Epithelial Cells(A) Engraftment of iPSC-MSCs in the lungs at different time points (1 hr, 4 hr, 8 hr, 24 hr, 96 hr) after local transplantation was examined using iPSC-MSCs transfected with GFP (GFP-iPSC-MSCs, green).(B) Flow cytometry analysis of the engraftment of GFP-iPSC-MSCs at different time points (1 hr, 4 hr, 8 hr, 24 hr, 96 hr). Experiments were carried out in triplicates.(C) Representative TEM micrograph showing the morphological changes in the mitochondria of first-generation bronchi after iPSC-MSC treatment (the red arrow indicates the swollen mitochondria).(D) Mitochondrial inner membrane potential for the mitochondria from lungs in each group was measured by flow cytometry.(E) Statistical analysis of the mitochondrial inner membrane potential quantified by the mean fluorescence intensity in the FL2 channel (n = 6).(F) Caspase 9 and caspase 3 activities related to apoptosis were measured in lung tissue from each group.(G) Quantification of caspase 9, caspase 3, and their cleaved products in lung tissues from each group (n = 3).Data are presented as the mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. BALF, bronchoalveolar lavage fluid; iPSC-MSCs, induced pluripotent stem cell-derived mesenchymal stem cells.

To further determine the effects of iPSC-MSCs on epithelial mitochondrial function, scanning transmission electron microscopy (TEM) and flow cytometry were performed to examine the morphological and functional changes in the epithelial mitochondria. These analyses showed that the administration of OVA led to swollen mitochondria ([Figure 2](#fig2){ref-type="fig"}C) and a decreased mitochondrial inner membrane potential in the lung ([Figures 2](#fig2){ref-type="fig"}D and 2E, p \< 0.001), whereas iPSC-MSC treatment improved the mitochondrial morphology and partially restored the mitochondrial inner membrane potential to a level similar to that in the PBS group ([Figures 2](#fig2){ref-type="fig"}C--2E). In addition, western blot analysis showed that the administration of OVA elevated the levels of caspase 3, caspase 9, and their cleaved products in lung tissue. In contrast, transplantation of iPSC-MSCs significantly reduced the expression of apoptosis-related products in the lungs, although it did not fully halt their expression ([Figures 2](#fig2){ref-type="fig"}F and 2G, p \< 0.01 or \< 0.001). These results demonstrate that iPSC-MSC treatment alleviates allergic airway inflammation by restoring bronchial mitochondrial function and preventing apoptosis in the lungs.

iPSC-MSCs Reduce CoCl~2~-Induced Mitochondrial Dysfunction and Apoptosis in Epithelial Cells *In Vitro* {#sec2.3}
-------------------------------------------------------------------------------------------------------

We examined the protective effects of iPSC-MSCs on epithelial cell mitochondrial dysfunction and apoptosis using the human BEAS-2B bronchial epithelium cell line. CoCl~2~, a hypoxia mimic that can induce the transcription of hypoxia-inducible factor target genes and cause hypoxic injury and dysfunction in epithelial cells, was used to treat BEAS-2B cells; CoCl~2~ (400 μM) was added to the culture medium for 12 hr to induce cellular apoptosis and impair the mitochondrial membrane potential. To test whether the protective effects of iPSC-MSCs were due to mitochondrial transfer to BEAS-2B cells via TNTs, non-specific potent actin polymerase inhibitors (cytochalasin D) and a connexin mimetic peptide (Gap26) were used. Administration of cytochalasin D and Gap26 did not affect iPSC-MSC viability (data not shown). BEAS-2B cells co-cultured with iPSC-MSCs exhibited significantly lower levels of apoptosis ([Figures 3](#fig3){ref-type="fig"}A and 3C, p \< 0.001) and mitochondrial membrane potential in response to CoCl~2~ ([Figures 3](#fig3){ref-type="fig"}B and 3D, p \< 0.001) than BEAS-2B cells cultured without iPSC-MSCs. However, these protective effects of iPSC-MSCs were partially abrogated by cytochalasin D and Gap26 ([Figures 3](#fig3){ref-type="fig"}A--3D). Similarly, co-culture with iPSC-MSCs greatly reduced the reactive oxygen species (ROS) levels in BEAS-2B cells induced by CoCl~2~. Gap26 treatment reversed these protective effects ([Figures 3](#fig3){ref-type="fig"}E and 3F, p \< 0.05). Taken together, these results show that iPSC-MSCs protect against CoCl~2~-induced mitochondrial dysfunction and apoptosis in BEAS-2B cells and that these protective effects may be due to mitochondrial function recovery via TNTs.Figure 3iPSC-MSCs Reduce CoCl~2~-Induced Mitochondrial Dysfunction and Apoptosis in Epithelial Cells *In Vitro*(A) Representative annexin V/propidium iodide (PI)-stained BEAS-2B cells analyzed by flow cytometry.(B) Representative mitochondrial membrane potential measured by flow cytometry.(C) Statistical analysis of the rate of BEAS-2B cell apoptosis (n = 6).(D) Statistical analysis of the mitochondrial membrane potential in each group (n = 6).(E) Representative reactive oxygen species in mitochondria (MitoROS) detected by flow cytometry.(F) Statistical analysis of MitoROS in BEAS-2B cells (n = 6).Data are presented as the mean ± SEM. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001. CytoD, cytochalasin D; iPSC-MSCs, induced pluripotent stem cell derived mesenchymal stem cells; PI, propidium iodide.

Mitochondrial Transfer from iPSC-MSCs to Epithelial Cells *In Vitro* and *In Vivo* {#sec2.4}
----------------------------------------------------------------------------------

To investigate mitochondrial transfer from iPSC-MSCs to epithelial cells, we first examined the TNT formation between iPSC-MSCs and BEAS-2B cells. We found that clear TNT-like structures were formed between normal BEAS-2B cells ([Figure 4](#fig4){ref-type="fig"}A), between CoCl~2~-treated BEAS-2B cells ([Figure 4](#fig4){ref-type="fig"}B), and between iPSC-MSCs ([Figure 4](#fig4){ref-type="fig"}C). Next, we treated BEAS-2B cells with or without CoCl~2~ and then co-cultured them with iPSC-MSCs. Thin, tubular, and membranous-based structures ranging in size from 20 μm to 100 μm were clearly observed between both the iPSC-MSCs and BEAS-2B cells treated with and without CoCl~2~ ([Figures 4](#fig4){ref-type="fig"}D and 4E). Time-lapse microscopy showed that the TNTs were involved in intercellular cytoplasmic component transportation and that the TNTs were originally formed by iPSC-MSCs. The number of TNTs from one iPSC-MSC was quantified under different conditions. More TNTs were formed between iPSC-MSCs and the damaged BEAS-2B cells than between the iPSC-MSCs and the normal BEAS-2B cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We next used MitoTracker Red to label mitochondria in iPSC-MSCs and 5(6)-carboxyfluorescein N-hydroxysuccinimidyl ester (CFSE) to label BEAS-2B cells (green) and then co-cultured the cells. iPSC-MSCs labeled with MitoTracker stretched out antennae and contacted the BEAS-2B cells labeled with CFSE ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Transfer of MitoTracker Red-labeled mitochondria from iPSC-MSCs to the CFSE-labeled BEAS-2B cells was observed at different time points ([Figure 4](#fig4){ref-type="fig"}F). Notably, mitochondrial transfer was detectable as early as 4 hr after co-culture, and the number of labeled mitochondria that were transferred into the BEAS-2B cells via TNTs increased over time ([Figures 4](#fig4){ref-type="fig"}F, [S2](#mmc1){ref-type="supplementary-material"}B, and S2C).Figure 4TNT Formation and Mitochondrial Transfer from iPSC-MSCs Labeled with MitoTracker into BEAS-2B Cells(A--C) TNT-like structures were observed between normal BEAS-2B cells (A), between damaged BEAS-2B cells (B), and between normal iPSC-MSCs (C).(D) TNTs were observed connecting iPSC-MSCs with normal BEAS-2B cells at 24 hr after co-culture.(E) More TNTs were observed between iPSC-MSCs and CoCl~2~-damaged BEAS-2B cells induced 24 hr after co-culture. TNTs were formed between normal BEAS-2B cells (b), damaged BEAS-2B cells (d), and normal N1-iPSC-MSCs (e); between normal N1-iPSC-MSCs and normal BEAS-2B cells (f, g, k); and between normal N1-iPSC-MSCs and damaged BEAS-2B cells (m, n, p, q, r, s, u).(F) iPSC-MSCs with MitoTracker Red-labeled mitochondria (red) were co-cultured with BEAS-2B cells (green). Mitochondrial transfer was detectable as early as 4 hr after co-culture. More mitochondria were transferred into BEAS-2B cells from iPSC-MSCs over time. BEAS-2B cells were labeled using CFSE (green) in (D)--(F). Experiments were carried out in triplicates.CFSE, 5(6)-carboxyfluorescein N-hydroxysuccinimidyl ester; iPSC-MSC, induced pluripotent stem cell-derived mesenchymal stem cells; OVA, ovalbumin; TNT, tunneling nanotube. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To avoid potential MitoTracker leakage, we transfected iPSC-MSCs with Mitochondria-GFP (mGFP) and then co-cultured the cells with CellTrace Violet-labeled BEAS-2B cells (blue). This experiment revealed TNT formation between the iPSC-MSCs ([Figure 5](#fig5){ref-type="fig"}A) and the movement of green mitochondria from mGFP-iPSC-MSCs to CoCl~2~-treated BEAS-2B cells ([Figure 5](#fig5){ref-type="fig"}B). GFP-positive mitochondria were clearly observed around the nuclei of BEAS-2B cells. In addition, flow cytometry analysis showed that the percentage of GFP-positive BEAS-2B cells was increased after 24 hr of co-culture and that up to 20% of BEAS-2B cells were positive for GFP after co-culture, suggesting that mitochondria were transferred from the mGFP-iPSC-MSCs to BEAS-2B cells ([Figure 5](#fig5){ref-type="fig"}C). Cytochalasin D and Gap26 treatment significantly reduced mitochondrial transfer from iPSC-MSCs to BEAS-2B cells, indicating that TNT plays a critical role in the regulation of mitochondrial transfer ([Figure 5](#fig5){ref-type="fig"}C). We next investigated whether engrafted iPSC-MSCs could donate mitochondria to bronchial epithelial cells in a mouse model of OVA-induced lung injury. The mGFP-iPSC-MSCs penetrated the OVA-induced lungs as quickly as 5 min after administration. GFP-labeled mitochondria started to appear in the lung cells at 1 hr post transplantation, and more mitochondria appeared in the lung tissue as time passed, even at 24 hr ([Figure 5](#fig5){ref-type="fig"}D). To determine whether the GFP-labeled mitochondria were located in alveolar epithelial cells, the alveolar epithelial cell-specific marker surfactant protein C (SPC) and the lung epithelial cell-specific marker Clara cell secretory protein (CCSP) were used to stain the epithelial cells at 24 hr after mGFP-iPSC-MSC administration. The staining revealed that the GFP-labeled mitochondria co-localized with both the alveolar epithelial and the bronchial cells ([Figures 5](#fig5){ref-type="fig"}E and 5F), demonstrating that the iPSC-MSCs donated their mitochondria to the epithelial cells of asthmatic mice. Taken together, these results suggest that iPSC-MSCs are capable of mitochondrial donation to injured epithelial cells via TNTs formed between these two cell types both *in vitro* and in mice.Figure 5Mitochondrial Transfer from mGFP-iPSC-MSCs into Epithelial Cells both *In Vitro* and in Mice(A) Representative image of TNTs between iPSC-MSCs showing mGFP-labeled mitochondria (mGFP-iPSC-MSC, green).(B) Representative image of mitochondria transferred from mGFP-iPSC-MSCs to damaged BEAS-2B cells induced by CoCl~2~ (CellTrace Violet-labeled, blue). The white arrow shows green mitochondria moving from mGFP-iPSC-MSCs to damaged BEAS-2B cells. The circled, enlarged region, indicated by the yellow arrow, shows the accumulation of green mitochondria in one BEAS-2B cell.(C) Mitochondrial transfer from mGFP-iPSC-MSCs to BEAS-2B cells was examined by fluorescence-activated cell sorting; cytochalasin D and Gap26 significantly suppressed the mitochondria transfer efficiency. Experiments were carried out in triplicates for (A)--(C).(D) Representative images of iPSC-MSCs containing mGFP labeled mitochondria (mGFP-iPSC-MSC, green) in OVA-induced lungs at different time points after administration. The GFP expression in the pulmonary alveoli gradually increased after iPSC-MSC administration in OVA-induced mice (n = 3).(E) Representative images for type II alveolar epithelial cells stained with SPC (alveolar epithelial cell-specific marker, red) and DAPI (nuclei, blue) at 24 hr; the enlarged region shows the presence of the GFP signal in SPC^+^ cells.(F) Representative images for bronchial epithelium stained with CCSP (lung epithelial cell-specific marker, red) and DAPI (nuclei, blue) at 24 hr; the enlarged region shows the presence of the GFP signal in CCSP^+^ cells.CCSP, Clara cell secretory protein; iPSC-MSC, induced pluripotent stem cell-derived mesenchymal stem cells; mGFP, mitochondrial targeting green fluorescence protein; SPC, surfactant protein C.

CX43 Mediates the TNT Formation and Mitochondrial Transfer from iPSC-MSCs to Epithelial Cells and the Protective Ability of iPSC-MSCs against OVA-Induced Allergic Airway Inflammation {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

It has been reported that CX43 contributes to mitochondrial transfer from BM-MSCs to alveoli in acute lung injury ([@bib16]). Therefore, we examined whether CX43 regulates the TNT formation and mitochondrial transfer from iPSC-MSCs to epithelial cells. We successfully overexpressed CX43 in the iPSC-MSCs by transfecting a CX43 plasmid ([Figure S3](#mmc1){ref-type="supplementary-material"}A). We co-cultured iPSC-MSCs with BEAS-2B cells labeled with CellTrace Violet (blue). Immunostaining results showed weak expression of endogenous CX43 (red) in GFP-iPSC-MSCs, but CX43 expression was remarkably increased in the CX43-GFP-iPSC-MSCs ([Figure 6](#fig6){ref-type="fig"}A). Interestingly, positive CX43 staining was also observed in the TNTs between GFP-iPSC-MSCs and BEAS-2B cells (arrows, [Figure 6](#fig6){ref-type="fig"}A). Western blot analysis revealed similar expression of CX43 in the BEAS-2B cells and GFP-iPSC-MSCs and higher levels of expression in the CX43-GFP-iPSC-MSCs ([Figure 6](#fig6){ref-type="fig"}B, p \< 0.001). CX43 was successfully silenced in the iPSC-MSCs using a plasmid expressing a short hairpin RNA against human CX43 ([Figure S3](#mmc1){ref-type="supplementary-material"}B). We found that, in co-cultures with BEAS-2B cells, more TNTs extended from the CX43-GFP-iPSC-MSCs than from the shCX43-iPSC-MSCs and GFP-iPSC-MSCs ([Figure 6](#fig6){ref-type="fig"}C). Importantly, inhibition of CX43 by short hairpin RNA (shRNA) diminished the TNT formation in shCX43-iPSC-MSCs, indicating that CX43 directly or indirectly regulates TNT formation in iPSC-MSCs ([Figure 6](#fig6){ref-type="fig"}C). Flow cytometry analysis also revealed more GFP-positive BEAS-2B cells upon co-culture with CX43-GFP-iPSC-MSCs than with shCX43-iPSC-MSCs or controls, suggesting that more mitochondrial transfer events occurred in the CX43-GFP-iPSC-MSCs than in the shCX43-iPSC-MSCs ([Figure 6](#fig6){ref-type="fig"}D). Our findings suggested that CX43 played an important role in the regulation of TNT formation for the mitochondrial transfer between iPSC-MSCs and BEAS-2B cells.Figure 6CX43 Mediates the Mitochondrial Transfer from iPSC-MSCs to Epithelial Cells and the Protective Effect of iPSC-MSCs on OVA-Induced Allergic Airway Inflammation(A) The representative expression of CX43 (red) in GFP-iPSC-MSCs and CX43-GFP-iPSC-MSCs upon co-culture with CellTrace Violet-labeled BEAS-2B cells (blue).(B) Western blot analysis of CX43 expression in BEAS-2B cells, GFP-iPSC-MSCs, and CX43-GFP-iPSC-MSCs (n = 3).(C) TNTs were observed connecting genetically modified iPSC-MSCs with CoCl~2~-damaged BEAS-2B cells (blue) 24 hr after co-culture. More TNTs (red frame) were observed from CX43-GFP-iPSC-MSCs than from shCX43-iPSC-MSCs. Total of 30 iPSC-MSCs in five to six view fields were counted for TNT number (n = 3).(D) Mitochondrial transfer from CX43-GFP-iPSC-MSCs and shCX43-iPSC-MSCs to BEAS-2B cells was determined by flow cytometry. Data are representative of three separate experiments.(E) Representative images of H&E and PAS staining for inflammation and mucus accumulation in lungs, respectively.(F) Statistical analysis of the inflammation score and mucus hypersecretion quantified by H&E/PAS scores (n = 6).(G) Inflammatory cell counts in BALF (n = 6).(H--J) The cytokine or Ig levels in BALF (H, n = 6), serum (I, n = 6) and lung homogenates (J, n = 6) as measured by ELISA.Data are presented as the mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}. BALF, bronchoalveolar lavage fluid; CX43, connexin 43; HE (Br), H&E-stained bronchia; HE (Ve), H&E-stained vessels; IL, interleukin; iPSC-MSC, induced pluripotent stem cell-derived mesenchymal stem cells; OVA, ovalbumin; PAS, periodic acid-Schiff; TSLP, thymic stromal lymphopoietin.

Subsequently, CX43-GFP-iPSC-MSCs were transplanted into OVA-induced model mice to examine their effects on allergic airway inflammation. Compared with the GFP-iPSC-MSCs, the CX43-GFP-iPSC-MSCs demonstrated superior performance by alleviating inflammation and decreasing the mucus secretion of hyperplastic goblet cells in OVA-induced lungs ([Figures 6](#fig6){ref-type="fig"}E and 6F, p \< 0.05). In addition, the levels of inflammatory cells in the BALF were decreased in the CX43-GFP-iPSC-MSC group compared with those in the GFP-iPSC-MSC group ([Figure 6](#fig6){ref-type="fig"}G, p \< 0.05). Similarly, the Th2 cytokine (IL-4, IL-5, and IL-13) levels in the lavage fluid, the IgE levels in serum, and the epithelium-derived cytokines (IL-33 and TSLP) in lung homogenates were dramatically reduced in the CX43-GFP-iPSC-MSC group compared with those in the GFP-iPSC-MSC group ([Figures 6](#fig6){ref-type="fig"}H--6J, p \< 0.05 or \< 0.01). Compared with the iPSC-MSCs infected with a non-targeting control (Shcontrol \[Sc\]-iPSC-MSCs), the shCX43-iPSC-MSCs did not exhibit the immunomodulatory effects that prevent airway inflammation and mucus secretion as determined by the H&E inflammation score and mucus hypersecretion quantified by PAS in a mouse model of asthma ([Figures 6](#fig6){ref-type="fig"}E and 6F). Furthermore, the administration of shCX43-iPSC-MSCs resulted in higher levels of eosinophils, lymphocytes, neutrophils, and total inflammatory cells ([Figure 6](#fig6){ref-type="fig"}G, p \< 0.05 or \< 0.001); higher levels of IL-4, IL-5, and IL-13 in the BALF ([Figure 6](#fig6){ref-type="fig"}H, p \< 0.001); higher serum levels of serum IgE and lower serum levels of IgG2a ([Figure 6](#fig6){ref-type="fig"}I, p \< 0.05 or \< 0.001); and higher levels of IL-33 and TSLP in the lung compared with those resulting from the administration of CX43-GFP-iPSC-MSCs ([Figure 6](#fig6){ref-type="fig"}J, p \< 0.001). In summary, these results demonstrate that CX43 is critical for the mitochondrial transfer between iPSC-MSCs and epithelial cells during the attenuation of allergic airway inflammation.

We next examined whether CX43 is involved in the iPSC-MSC-mediated protection against OVA-induced mitochondrial dysfunction in allergic airway inflammation. Compared with that in the iPSC-MSC group, transfection with CX43 further restored mitochondrial inner membrane potential (p \< 0.05), whereas the shCX43-iPSC-MSCs decreased this potential in OVA-induced mitochondrial dysfunction in the lung ([Figures 7](#fig7){ref-type="fig"}A and 7B). Furthermore, western blot analysis showed that overexpression of CX43 enhanced the iPSC-MSC-mediated inhibition of caspase 3 and caspase 9 expression as well as that of their cleaved products in lung tissue induced by OVA, whereas shCX43-iPSC-MSC treatment reversed these effects ([Figures 7](#fig7){ref-type="fig"}C and 7D).Figure 7CX43 Mediates the Effects of iPSC-MSCs on Mitochondrial Dysfunction in a Mouse Model of Asthma(A) Representative mitochondrial inner membrane potential measured by flow cytometry (n = 6).(B) Statistical analysis of the mitochondrial inner membrane potential quantified by mean fluorescence intensity (n = 6).(C) Western blot analysis of caspase 9 and caspase 3 activity.(D) Quantification of caspase 9, caspase 3, and their cleaved products in lung tissues treated with genetically modified iPSC-MSCs (n = 3).Data are presented as the mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. BALF, bronchoalveolar lavage fluid; CX43, connexin 43; iPSC-MSC, induced pluripotent stem cell-derived mesenchymal stem cells; OVA, ovalbumin.

Taken together, these findings demonstrate that overexpression of CX43 enhances the iPSC-MSC-mediated attenuation of allergic airway inflammation and rescue of mitochondrial dysfunction, whereas silencing CX43 in iPSC-MSCs partially abrogates these protective effects. These results suggest that CX43 is essential for TNT formation and iPSC-MSC-mediated mitochondrial transfer, which alleviates the symptoms of allergic airway inflammation by restoring bronchial mitochondrial function and preventing apoptosis in the lungs.

Discussion {#sec3}
==========

MSC-based therapy has shown promising results for treating asthmatic inflammation by several mechanisms. This study focused on iPSC-MSC function in rescuing bronchial epithelial bioenergetics in asthma. We found that local transplantation of iPSC-MSCs alleviated asthma inflammation and protected the epithelial cells in mice via donating mitochondria to the dysfunctional mitochondrial epithelial cells. Mitochondria were transferred from iPSC-MSCs to epithelial cells via CX43-mediated TNTs, which bridged these two types of cells. The mitochondrial donation by iPSC-MSCs prevented the apoptosis of epithelial cells by restoring their mitochondrial function, alleviating the asthma inflammation caused by allergic or hypoxic conditions. Compared with MSCs isolated from BM and fetuses, we previously reported that iPSC-MSCs hold several advantages, including a higher proliferative capacity, higher differentiation potential, stronger immune privilege, and longer life span ([@bib12], [@bib24], [@bib38]). The finding of this study is that CX43 contributes to mitochondrial transfer from iPSC-MSCs to epithelial cells via regulating TNT formation in asthma.

Epithelial cells mediate the innate and adaptive immune systems by releasing chemokines, cytokines, and alarmins ([@bib14]). The airway epithelium is considered an essential controller of the inflammatory, immune, and regenerative responses to the allergens, viruses, and environmental pollutants that contribute to asthma pathogenesis ([@bib20]). Increasing evidence shows that MSC transplantation can functionally ameliorate lung injury ([@bib10], [@bib39], [@bib40]). Our previous studies demonstrated that intravenous injection of iPSC-MSCs inhibited allergic airway inflammation and permitted a rebalancing of the immune response in a mouse model ([@bib37], [@bib41]). In this study, iPSC-MSCs were intratracheally injected into mice with OVA-induced asthma to investigate the effects of iPSC-MSCs on epithelial cells in asthma. Compared with that achieved with intravenous injection, the intratracheal injection of MSCs for the treatment of lung diseases may result in greater retention in the targeted tissue ([@bib2], [@bib3]). We found that treatment with iPSC-MSCs dramatically reduced the expression of the epithelial cytokines IL-33 and TSLP and inhibited the apoptosis of BEAS-2B cells under CoCl~2~ challenge, suggesting that local transplantation of iPSC-MSCs significantly inhibits asthma inflammation in the OVA-induced asthma mouse model.

Mitochondrial dysfunction in epithelial cells is reported responsible for allergic airway inflammation ([@bib17], [@bib19], [@bib32]). Treatment with mitoTEMPO, a mitochondrial-targeted antioxidant, inhibits OVA-induced allergic asthma in mice via attenuating mitochondrial ROS levels in epithelial cells ([@bib17]). Therefore, targeting mitochondrial dysfunction may be an approach for allergic airway inflammation therapy. Previous studies have shown that MSCs can alleviate mitochondrial dysfunction in many cell types ([@bib6], [@bib23], [@bib27]). In the current study, administration of OVA led to swollen mitochondria and a decreased mitochondrial inner membrane potential in epithelial cells, indicating mitochondrial dysfunction. In contrast, transplantation of iPSC-MSCs greatly improved the mitochondrial morphology and partially restored the mitochondrial inner membrane potential. Furthermore, co-culture with iPSC-MSCs also reduced CoCl~2~-induced mitochondrial dysfunction in epithelial cells, suggesting that the iPSC-MSC-mediated inhibition of asthma inflammation is due to the alleviation of mitochondrial dysfunction in epithelial cells. However, how iPSC-MSCs rescue mitochondrial dysfunction in epithelial cells remains largely unknown. Recent studies, including our own, have shown that MSCs can donate functional mitochondria to injured corneal epithelial cells and cardiomyocytes via TNT formation ([@bib18], [@bib29], [@bib44]). Here, we showed that iPSC-MSCs can donate mitochondria to epithelial cells with OVA- or CoCl~2~-induced mitochondrial dysfunction via TNTs, which bridge iPSC-MSCs and injured epithelial cells and improve their mitochondrial function. Enhanced mitochondrial membrane potential may prevent cellular apoptotic processes, which could reduce allergic airway inflammation by preventing the release of pro-inflammatory factors ([@bib4], [@bib13]). These findings are in agreement with those of our previous studies showing that mitochondria transferred from iPSC-MSCs are functional and can inhibit cigarette smoke-induced lung injury and rescue anthracycline-induced cardiomyopathy ([@bib22], [@bib44]). Furthermore, treatment with the TNT inhibitors significantly reduced the mitochondrial transfer efficiency from iPSC-MSCs to epithelial cells, indicating that TNT is essential for mitochondrial transfer.

Although there is considerable interest in investigating MSC mitochondrial transfer, the molecular regulators mediating mitochondrial transfer are not fully understood. Some molecular regulators that govern mitochondrial transfer have been identified. MIRO1 plays a critical role in regulating the mitochondrial transfer of MSCs, and overexpression of MIRO1 greatly enhances the mitochondrial transfer efficiency of iPSC-MSCs ([@bib1], [@bib44]). The microtubule motor protein kinesin family member 5B (KIF5B) has been considered to be a regulator of mitochondrial transfer ([@bib34]). [@bib16] found that BM-MSCs donated mitochondria to alveolar progenitor cells via CX43 gap junctions in a mouse model of acute lung injury. In contrast, [@bib35] found that CX43 had no impact on the mitochondrial transfer of BM-MSCs. These contradictory findings may be due to the different sources of MSCs and the culture of MSCs under different conditions. There is increasing evidence for the existence of CX43 channels in TNTs, which could constitute a cellular strategy to regulate intercellular communication and contribute to the maintenance of homeostasis ([@bib15], [@bib28], [@bib33]). We found that CX43 is upregulated in mouse lungs during asthma ([@bib42]). It has been reported that CX43 can stimulate TNT formation in HeLa cells ([@bib26]). However, the pathophysiological implications of CX43-dependent channel activity in TNTs between iPSC-MSCs and epithelial cells remain to be clarified, and how CX43 behaves in the mitochondrial transfer of iPSC-MSCs in asthma-associated contexts is still unknown. To determine the role of CX43 in TNT formation and mitochondrial transfer between iPSC-MSCs and bronchial epithelial cells, genetic modification was employed to modify CX43 expression in iPSC-MSCs. These modifications demonstrated that, compared with iPSC-MSCs, overexpression of CX43 in iPSC-MSCs enhanced the TNT formation between iPSC-MSCs and epithelial cells *in vitro*, alleviated allergic airway inflammation, and significantly increased the mitochondrial transfer efficiency to epithelial cells, indicating that CX43 is a key regulator of TNT formation and mitochondrial transfer. Furthermore, silencing CX43 reduced TNF formation and the immunomodulatory effects of iPSC-MSCs during allergic airway inflammation. However, CX43 silencing did not completely prevent mitochondrial transfer from iPSC-MSCs to epithelial cells, indicating that other mechanisms are also involved in regulating mitochondrial transfer.

There are some limitations of this study. First, mitochondrial transfer is bidirectional, and whether the mitochondria in injured epithelial cells are transferred to iPSC-MSCs has not been elucidated. Second, although our results demonstrate that CX43 mediates the mitochondrial transfer efficacy of iPSC-MSCs, the signaling pathways involved in mitochondrial transfer have yet to be investigated. Detailed *in vivo* studies on the mitochondrial transfer from iPSC-MSCs to pulmonary alveoli in asthma require further investigation.

In conclusion, this study shows that, in addition to the immunomodulatory effect, the beneficial effect of iPSC-MSCs on allergic airway inflammation is in part due to mitochondrial transfer. Furthermore, CX43 is vital for regulating the TNT formation and mitochondrial transfer efficiency of iPSC-MSCs. Our study provides broader insight into the potential use of iPSC-MSCs as a treatment strategy for asthma.

Experimental Procedures {#sec4}
=======================

Detailed descriptions of the methods are listed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell Culture {#sec4.1}
------------

Two types of human iPSC-MSCs (N1-iPSC-MSCs and iMR90-iPSC-MSCs) were generated and cultured according to a previously described protocol ([@bib24]). The human bronchial epithelium cell line (BEAS-2B cells) obtained from American Type Culture Collection (ATCC) was cultured in DMEM/F12 (HyClone, Logan, UT) supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco, Carlsbad, CA) at 37°C, 5% CO~2~, and 95% humidity.

Mouse Model of Asthma {#sec4.2}
---------------------

All procedures involving animals were performed in accordance with the guidelines for animal experiments and approved by the Sun Yat-sen University Institutional Animal Care and Use Committee (approval no. 2013-61). The mouse model of OVA-induced asthma was modified according to our previous study ([@bib37]), iPSC-MSCs were intratracheally delivered to the mice 24 hr prior to OVA challenge ([Figure S4](#mmc1){ref-type="supplementary-material"}).

Histological Analysis of the Lungs {#sec4.3}
----------------------------------

All the mice were sacrificed 6 hr after the last OVA challenge. H&E and PAS staining were performed to examine the inflammatory infiltrates and mucus accumulation.

Measurement of Inflammatory Cytokine and Ig Levels {#sec4.4}
--------------------------------------------------

BALF and serum were collected as previously described ([@bib37]). The levels of various inflammatory cytokines (IL-4, IL-5 and IL-13 in BALF; IL-33 and TSLP in lung homogenate) as well as those of serum Ig (OVA-specific IgE, IgG1, and IgG2a) were measured.

Assessment of iPSC-MSC Engraftment {#sec4.5}
----------------------------------

The engraftment of GFP-iPSC-MSCs in the lungs of mice at different time points (1 hr, 4 hr, 8 hr, 24 hr, and 96 hr) after local injection (n = 3) were examined by fluorescence microscopy (ZEISS LSM 800, Oberkochen, Germany) and flow cytometry (Beckman Coulter, Hercules, CA).

Assessment of Mitochondrial Inner Membrane Potential {#sec4.6}
----------------------------------------------------

BEAS-2B cells or mitochondria from lungs were incubated with the J-aggregate-forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1, Sigma-Aldrich, St. Louis, MO) and then measured by flow cytometry.

Western Blot Analysis {#sec4.7}
---------------------

Caspase 3 and caspase 9 levels in the lungs were detected with antibodies of caspase 3, cleaved caspase 3 (Asp175), caspase 9, and cleaved caspase 9 (Asp353) (Cell Signaling Technology, Beverly, MA) and the corresponding secondary antibodies (Santa Cruz Biotechnology, Dallas, TX) as previously described ([@bib42]). The CX43 levels in the iPSC-MSCs were detected with an anti-CX43 antibody (BioLegend, San Diego, CA).

Overexpression and Silencing of CX43 in iPSC-MSCs {#sec4.8}
-------------------------------------------------

To determine whether CX43 is involved in the regulation of mitochondrial transfer of iPSC-MSCs, CX43-overexpressing iPSC-MSCs were prepared by lentiviral infection as previously described ([@bib25]). CX43 in iPSC-MSCs was knocked down in iPSC-MSCs by shRNA (Vigene Biosciences, Rockville, MD). The genetically modified iPSC-MSCs were co-cultured with CellTrace Violet (Thermo Fisher Scientific, Boston, MA)-labeled BEAS-2B cells for validation before further transplantation.

Statistical Analysis {#sec4.9}
--------------------

All experimental data are presented as the mean ± SEM. p \< 0.05 was considered statistically significant.
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